Skip to main content

Table 1 Baseline characteristics

From: A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

 

N = 10

Age, median (range), years

67.5 (46–82)

Sex, n

 Male

7

 Female

3

ECOG performance status, n

 0

4

 1

6

Myelofibrosis type, n

 Primary MF

6

 Post-ET

3

 Post-PV

1

DIPSS risk status, n

 High

1

 Intermediate-2

6

 Intermediate-1

3

Transfusion-dependent at study entry

 Yes

3

 No

7

  1. DIPSS International Working Group-Myeloproliferative Neoplasms Research and Treatment Dynamic International Prognostic Scoring System, ECOG Eastern Cooperative Oncology Group performance status, PV polycythemia vera